Advertisement
Screener

Amphastar Pharmaceuticals, Inc. (AMPH) Overview

Amphastar Pharmaceuticals, Inc. (AMPH) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 0.67; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 0.14; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 0.37; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 0.64; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$16.03$18.27$20.83$23.75$27.08$30.872025-11-062026-11-06$16.03$21.41$28.61$38.23$51.08$68.252021-11-082026-11-06$11.59$16.52$23.56$33.58$47.87$68.252016-11-072026-11-06$8.26$12.60$19.22$29.32$44.73$68.252014-06-252026-11-06$8.26$12.60$19.22$29.32$44.73$68.252014-06-252026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$28.50
Previous close
$26.68
Change
$1.82
Change (%)
6.82%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

AMPH
-0.37%
S&P 500
(m)

1 year

AMPH
-0.89%
S&P 500
(m)

3 years

AMPH
-41.99%
S&P 500
(m)

5 years

AMPH
+38.89%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 0.67

0.060.260.460.650.8531 Mar 2025: estimate (m); actual 0.5131 Mar 2025(m)30 Jun 2025: estimate (m); actual 0.6430 Jun 2025(m)30 Sept 2025: estimate (m); actual 0.3730 Sept 2025(m)31 Mar 2026: estimate (m); actual 0.1431 Mar 2026(m)30 Jun 2026: estimate (m); actual 0.6730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)0.67(m)(m)
1 Jan 202631 Mar 2026(m)0.14(m)(m)
1 Jul 202530 Sept 2025(m)0.37(m)(m)
1 Apr 202530 Jun 2025(m)0.64(m)(m)
1 Jan 202531 Mar 2025(m)0.51(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 2.03

1.171.692.212.723.2431 Dec 2021: estimate (m); actual 1.2531 Dec 2021(m)31 Dec 2022: estimate (m); actual 1.7431 Dec 2022(m)31 Dec 2023: estimate (m); actual 2.6031 Dec 2023(m)31 Dec 2024: estimate (m); actual 3.0631 Dec 2024(m)31 Dec 2025: estimate (m); actual 2.0331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)2.03(m)(m)
1 Jan 202431 Dec 2024(m)3.06(m)(m)
1 Jan 202331 Dec 2023(m)2.60(m)(m)
1 Jan 202231 Dec 2022(m)1.74(m)(m)
1 Jan 202131 Dec 2021(m)1.25(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 183.90M ■ Earnings 30.35M — Profit margin 16.50%

-23.02M2.8%56.27M7.7%135.57M12.6%214.86M17.5%30 Sept 2025: revenue 191.84M; earnings 17.35M; profit margin 9.04%30 Sept 202531 Dec 2025: revenue 183.10M*; earnings 24.43M*; profit margin 13.34%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 171.17M; earnings 6.42M; profit margin 3.75%31 Mar 202630 Jun 2026: revenue 183.90M; earnings 30.35M; profit margin 16.50%30 Jun 2026

31 Dec 2025 ■ Revenue 719.89M ■ Earnings 98.09M — Profit margin 13.63%

-87.84M12.6%214.71M16.0%517.26M19.4%819.80M22.8%31 Dec 2022: revenue 498.99M; earnings 91.39M; profit margin 18.31%31 Dec 202231 Dec 2023: revenue 644.39M; earnings 137.54M; profit margin 21.34%31 Dec 202331 Dec 2024: revenue 731.97M; earnings 159.52M; profit margin 21.79%31 Dec 202431 Dec 2025: revenue 719.89M; earnings 98.09M; profit margin 13.63%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$28.50(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$28.50High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning AMPH

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-13; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
163.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
553.64K
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
9.70%*
Total return · month
21.22%*
Total return · quarter
28.83%*
Total return · half year
40.35%*
Total return · year to date
-0.37%*
Total return · 1 year
-0.89%*
Total return · 3 years
-41.99%*
Total return · 5 years
38.89%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Amphastar Pharmaceuticals, Inc. Overview

View more →

(m)

(m)

SEC CIK
1297184
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
11570 SIXTH STREET, RANCHO CUCAMONGA, California, 91730, United States
Fiscal year end
1231
Phone
909-980-9484

Similar stocks

Stock NameCountryMarket CapPE Ratio
Seaport Therapeutics, Inc. (SPTX)United States$1.131B
Alto Neuroscience, Inc. (ANRO)United States$1.065B-11.02
MANNKIND CORP (MNKD)United States$1.058B-30.41
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Jaguar Health, Inc. (JAGX)United States$1.184B
Savara Inc (SVRA)United States$1.044B-9.10
MoonLake Immunotherapeutics (MLTX)Switzerland$1.031B-5.43
Pacira BioSciences, Inc. (PCRX)United States$1.020B69.03
Janux Therapeutics, Inc. (JANX)United States$1.019B-9.15
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87